A Phase I Dose Escalation Study of Peptide Vaccines With Activity Against Human Cytomegalovirus.

Trial Profile

A Phase I Dose Escalation Study of Peptide Vaccines With Activity Against Human Cytomegalovirus.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Agatolimod (Primary) ; Cytomegalovirus vaccines (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jun 2012 Actual patient number 68 added as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top